Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
slaidlaw@well.ox.ac.uk

Research groups

Carroll Group: High Consequence Emerging Viruses Group

Stephen Laidlaw

PhD

Postdoctoral Research Scientist

I am a postdoc currently researching the immune response and antivirals against SARS-CoV2 and other coronaviruses.

Recent publications

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
Journal article

Cornish K. et al, (2024), Open biology, 14
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Journal article

Barnes E. et al, (2023), Nature Medicine, 29, 1760 - 1774
Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery
Preprint

Ali M. et al, (2023)
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Journal article

Brewitz L. et al, (2023), Journal of Medicinal Chemistry, 66, 2663 - 2680
A prototype lateral flow assay for detection of orthopoxviruses.
Journal article

Ulaeto DO. et al, (2022), The Lancet. Infectious diseases, 22, 1279 - 1280

More publications